DNAJC13
Basic information
Region (hg38): 3:132417502-132539032
Links
Phenotypes
GenCC
Source:
- hereditary late onset Parkinson disease (Supportive), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Parkinson disease 21 | AD | Neurologic | Response to levodopa has been described | Neurologic | 24218364; 25186792 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the DNAJC13 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 16 | 23 | ||||
missense | 98 | 11 | 10 | 119 | ||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 3 | 8 | 11 | |||
non coding | 103 | 105 | ||||
Total | 0 | 0 | 99 | 29 | 119 |
Variants in DNAJC13
This is a list of pathogenic ClinVar variants found in the DNAJC13 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
3-132434209-C-CA | Benign (Oct 05, 2019) | |||
3-132434272-G-C | Benign (Jul 10, 2018) | |||
3-132434289-C-G | Benign (Jul 09, 2018) | |||
3-132434331-AGCAAAGATCGTGC-A | Benign (Jul 14, 2018) | |||
3-132434384-C-CA | Benign (Oct 07, 2019) | |||
3-132434489-T-TAG | Benign (Jul 09, 2018) | |||
3-132434570-A-G | not specified | Uncertain significance (May 27, 2022) | ||
3-132434768-A-G | Benign (Jul 09, 2018) | |||
3-132446211-T-A | Benign (Jul 09, 2018) | |||
3-132446334-A-T | Benign (Jul 09, 2018) | |||
3-132446504-A-G | DNAJC13-related disorder | Uncertain significance (Apr 29, 2023) | ||
3-132446505-T-A | not specified | Uncertain significance (Dec 01, 2022) | ||
3-132446507-C-T | not specified | Uncertain significance (Feb 10, 2022) | ||
3-132446514-T-C | Likely benign (Jun 15, 2018) | |||
3-132446756-AG-A | Benign (Jul 14, 2018) | |||
3-132447161-A-G | Benign (Jul 09, 2018) | |||
3-132447328-A-G | not specified | Uncertain significance (Nov 21, 2022) | ||
3-132447336-A-G | not specified | Uncertain significance (Jun 06, 2023) | ||
3-132447373-C-T | DNAJC13-related disorder | Uncertain significance (Feb 20, 2023) | ||
3-132447393-C-G | not specified | Uncertain significance (Sep 15, 2021) | ||
3-132447393-C-T | not specified | Uncertain significance (Dec 13, 2021) | ||
3-132447422-T-G | not specified | Benign (Jul 05, 2018) | ||
3-132447435-A-G | not specified | Uncertain significance (Feb 21, 2024) | ||
3-132447458-T-G | not specified • DNAJC13-related disorder | Likely benign (-) | ||
3-132447465-G-A | not specified | Uncertain significance (Sep 22, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
DNAJC13 | protein_coding | protein_coding | ENST00000260818 | 55 | 121507 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.00 | 2.49e-9 | 125721 | 0 | 26 | 125747 | 0.000103 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 2.28 | 945 | 1.16e+3 | 0.812 | 0.0000591 | 14770 |
Missense in Polyphen | 142 | 251.79 | 0.56396 | 3274 | ||
Synonymous | 0.722 | 383 | 401 | 0.954 | 0.0000206 | 4150 |
Loss of Function | 9.16 | 17 | 129 | 0.131 | 0.00000688 | 1625 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000427 | 0.000424 |
Ashkenazi Jewish | 0.0000992 | 0.0000992 |
East Asian | 0.000163 | 0.000163 |
Finnish | 0.0000462 | 0.0000462 |
European (Non-Finnish) | 0.0000897 | 0.0000879 |
Middle Eastern | 0.000163 | 0.000163 |
South Asian | 0.0000374 | 0.0000327 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Involved in membrane trafficking through early endosomes, such as the early endosome to recycling endosome transport implicated in the recycling of transferrin and the early endosome to late endosome transport implicated in degradation of EGF and EGFR (PubMed:18256511, PubMed:18307993). Involved in the regulation of endosomal membrane tubulation and regulates th dynamics of SNX1 on the endosomal membrane; via association with WASHC2 may link the WASH complex to the retromer SNX-BAR subcomplex (PubMed:24643499). {ECO:0000269|PubMed:18256511, ECO:0000269|PubMed:18307993, ECO:0000269|PubMed:24643499}.;
- Disease
- DISEASE: Parkinson disease (PARK) [MIM:168600]: A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features. {ECO:0000269|PubMed:24218364, ECO:0000269|PubMed:25393719}. Note=The gene represented in this entry may be involved in disease pathogenesis. Genetic variants in DNAJC13 (PubMed:24218364, PubMed:25393719) and TMEM230 (PubMed:27270108) have been found in the same large multigenerational family with adult-onset Parkinson disease. The pathological role of each gene and therefore the exact molecular basis of the disease is unclear. {ECO:0000305|PubMed:27270108}.;
- Pathway
- Neutrophil degranulation;Innate Immune System;Immune System
(Consensus)
Recessive Scores
- pRec
- 0.139
Intolerance Scores
- loftool
- 0.372
- rvis_EVS
- 0.17
- rvis_percentile_EVS
- 65.77
Haploinsufficiency Scores
- pHI
- 0.418
- hipred
- N
- hipred_score
- 0.476
- ghis
- 0.568
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.781
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Dnajc13
- Phenotype
Gene ontology
- Biological process
- osteoblast differentiation;receptor-mediated endocytosis;endosome organization;protein transport;neutrophil degranulation;regulation of early endosome to recycling endosome transport;regulation of early endosome to late endosome transport
- Cellular component
- lysosomal membrane;cytosol;plasma membrane;endosome membrane;membrane;secretory granule membrane;early endosome membrane;azurophil granule membrane;intracellular membrane-bounded organelle;extracellular exosome;WASH complex
- Molecular function
- protein binding